Neos Therapeutics Inc. (NASDAQ:NEOS) saw a large increase in short interest in September. As of September 30th, there was short interest totalling 1,731,537 shares, an increase of 27.9% from the September 15th total of 1,353,962 shares. Based on an average trading volume of 205,683 shares, the days-to-cover ratio is currently 8.4 days. Approximately 19.9% of the shares of the company are short sold.
Several analysts recently issued reports on the company. Zacks Investment Research raised Neos Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a report on Thursday. BMO Capital Markets reissued a “buy” rating and issued a $15.00 price target on shares of Neos Therapeutics in a report on Tuesday, September 20th. Five research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus price target of $20.94.
Shares of Neos Therapeutics (NASDAQ:NEOS) opened at 6.67 on Friday. Neos Therapeutics has a 52 week low of $6.33 and a 52 week high of $18.84. The company’s market cap is $107.19 million. The firm’s 50-day moving average price is $7.05 and its 200 day moving average price is $8.63.
Neos Therapeutics (NASDAQ:NEOS) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.16) by $0.49. Neos Therapeutics had a negative return on equity of 80.10% and a negative net margin of 968.81%. The business had revenue of $1.49 million for the quarter, compared to analyst estimates of $1.48 million. On average, equities analysts predict that Neos Therapeutics will post ($5.39) EPS for the current fiscal year.
In other news, CFO Richard I. Eisenstadt bought 3,710 shares of the firm’s stock in a transaction dated Thursday, August 25th. The stock was bought at an average price of $6.82 per share, for a total transaction of $25,302.20. Following the transaction, the chief financial officer now owns 3,710 shares in the company, valued at $25,302.20. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 4.85% of the stock is owned by insiders.
Several institutional investors have recently bought and sold shares of NEOS. ProShare Advisors LLC boosted its position in Neos Therapeutics by 10.0% in the second quarter. ProShare Advisors LLC now owns 13,622 shares of the company’s stock valued at $126,000 after buying an additional 1,233 shares in the last quarter. Geode Capital Management LLC boosted its position in Neos Therapeutics by 5.4% in the first quarter. Geode Capital Management LLC now owns 38,698 shares of the company’s stock valued at $417,000 after buying an additional 1,997 shares in the last quarter. State Street Corp boosted its position in Neos Therapeutics by 20.0% in the first quarter. State Street Corp now owns 64,825 shares of the company’s stock valued at $698,000 after buying an additional 10,786 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Neos Therapeutics by 73.1% in the second quarter. Bank of New York Mellon Corp now owns 38,008 shares of the company’s stock valued at $353,000 after buying an additional 16,046 shares in the last quarter. Finally, Teachers Advisors Inc. boosted its position in Neos Therapeutics by 289.6% in the second quarter. Teachers Advisors Inc. now owns 21,924 shares of the company’s stock valued at $203,000 after buying an additional 16,296 shares in the last quarter. 37.73% of the stock is owned by institutional investors and hedge funds.
Neos Therapeutics Company Profile